Disease · MONDO_0005139

morbid obesity

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. morbid obesity. Diseases, record MONDO_0005139. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005139

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: morbid obesity; Open Targets
Open Targets ID: MONDO_0005139; Open Targets
Other names: Morbid Obesities, Morbid obesity (disorder), Obesities, Morbid, Obesity, Morbid, Severe obesity; Open Targets
Disease Ontology: DOID:11981; Disease Ontology
MeSH: D009767; MeSH
Highest stage of its drugs: Phase 3, for 1 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EXENATIDE	CHEMBL414357	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PHENTERMINE	CHEMBL1574	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
AMINO ACIDS	CHEMBL1201498		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
BIFIDOBACTERIUM SPP.	CHEMBL4297912		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
DESFLURANE	CHEMBL1200733	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOMIDATE	CHEMBL681	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets58

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 58

See all 58 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03029715	Anaesthesia for Laparoscopic Sleeve Gastrectomy	Not applicable	100	2020-09-16	Obese	DESFLURANE, DEXMEDETOMIDINE, PROPOFOL, REMIFENTANIL	Its record names the disease	ClinicalTrials.gov
NCT06934655	Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth	Phase 3	150		Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT04298203	Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity	Phase 2	100		Obesity	PHENTERMINE, TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT03029572	Micro-nutritional Status and Gut Microbiota in Morbidly Obese Patients Before and After Gastric Bypass	Not applicable	90		Obesity, Bariatric Surgery Candidate	OMEGA-3 FATTY ACIDS	Its record names the disease	ClinicalTrials.gov
NCT01930019	The Influence of Induction Anesthetic Agents on Serum Cortisol Concentration in Morbidly Obese Patients.	Not applicable	82		Obesity	ETOMIDATE, THIOPENTAL	Its record names the disease	ClinicalTrials.gov
NCT03747094	Sedation of Morbidly Obese for Balloon Insertion	Not applicable	70		Morbid Obesity	FENTANYL, KETAMINE	Its record names the disease	ClinicalTrials.gov
NCT04986631	Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP	Early phase 1	65		Obesity, Childhood	TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT06052111	Dexmedetomidine vs Fentanyl on Time to Extubation in Patients Undergoing Laparoscopic Sleeve Gastrectomy	Not applicable	64		Dexmedetomidine, Fentanyl, Time to Extubation, Morbid Obesity, Laparoscopic Sleeve Gastrectomy	DEXMEDETOMIDINE, FENTANYL	Its record names the disease	ClinicalTrials.gov
NCT00872378	The Effects of Exenatide After Gastric Restriction	Phase 2/3	28		Morbid Obesity	EXENATIDE	Its record names the disease	ClinicalTrials.gov
NCT07128719	Study Effects of Preoperative Modafinil on Recovery Profile of Morbidly Obese Patients Scheduled for Bariatric Surgery if it Can Enhance Recovery From Anesthesia	Not applicable	20		Obese Adolescents, Bariatric Surgery	MODAFINIL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Intravenous Anaesthesia vs Inhalation Anaesthesia: serious adverse events	0 of 50	0 of 50	100	NCT03029715

Source Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
29223575	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005139

GET https://conductscience.org/api/diseases/v1/MONDO_0005139/targets?page=2

API reference For AI assistants